The Food and Drug Administration has approved the use of Gilead Sciences’ Veklury, or remdesivir, as a COVID-19 treatment for children as young as 28 days old, making it the first COVID-19 medication to have full approval for children younger than 12.
The decision applies to children with mild to moderate COVID-19 who are at high risk for progression to severe disease and those hospitalized with COVID-19.
Read more in Reuters.